245 research outputs found
Real World Interpretations of Quantum Theory
I propose a new class of interpretations, {\it real world interpretations},
of the quantum theory of closed systems. These interpretations postulate a
preferred factorization of Hilbert space and preferred projective measurements
on one factor. They give a mathematical characterisation of the different
possible worlds arising in an evolving closed quantum system, in which each
possible world corresponds to a (generally mixed) evolving quantum state. In a
realistic model, the states corresponding to different worlds should be
expected to tend towards orthogonality as different possible quasiclassical
structures emerge or as measurement-like interactions produce different
classical outcomes. However, as the worlds have a precise mathematical
definition, real world interpretations need no definition of quasiclassicality,
measurement, or other concepts whose imprecision is problematic in other
interpretational approaches. It is natural to postulate that precisely one
world is chosen randomly, using the natural probability distribution, as the
world realised in Nature, and that this world's mathematical characterisation
is a complete description of reality.Comment: Minor revisions. To appear in Foundations of Physic
Meditation-induced bliss viewed as release from conditioned neural (thought) patterns that block reward signals in the brain pleasure center
The nucleus accumbens orchestrates processes related to reward and pleasure,
including the addictive consequences of repeated reward (e.g., drug addiction and
compulsive gambling) and the accompanying feelings of craving and anhedonia.
The neurotransmitters dopamine and endogenous opiates play interactive roles in
these processes. They are released by natural rewards (i.e., food, water, sex, money,
play, etc.) and are released or mimicked by drugs of abuse. Repeated drug use
induces conditioned down-regulation of these neurotransmitters, thus causing
painful suppression of everyday pleasure. As with many spiritual traditions,
Buddhism provides strong advice against the pursuit of worldly pleasures to
attain the ââgood life.ââ In contrast, many forms of meditation give rise to an
immense and abiding joy. Most of these practices involve ââstilling the mind,ââ
whereby all content-laden thought (e.g., fantasies, daydreams, plans) ceases, and
the mind enters a state of openness, formlessness, clarity, and bliss. This can be
explained by the Buddhist suggestion that almost all of our everyday thoughts are
a form of addiction. It follows that if we turn off this internal ââgossip of ego,ââ we
will find relief from the biochemical dopamine/opiate down-regulation, which is,
perhaps, the perpetual concomitant of our daily rumination
Meditation-induced bliss viewed as release from conditioned neural (thought) patterns that block reward signals in the brain pleasure center
An intervention study to prevent relapse in patients with schizophrenia
Purpose: To determine whether the use of relapse prevention plans (RPPs) in nursing practice is an effective intervention in reducing relapse rates among patients with schizophrenia. Design and Methods: Experimental design. Patients with schizophrenia (or a related psychotic disorder) and nurses from three mental health organizations were randomly assigned to either an experimental (RPP) or control condition (care as usual). The primary outcome measure was the psychotic relapses in the research groups. Results: The relapse rates in the experimental and control groups after 1-year follow-up were 12.5% and 26.2%, respectively (p=.12, ns). The relative risk of a relapse in the experimental versus the control group was 0.48(ns). Conclusions: In this study no statistically significant effects of the intervention were found. Effectiveness research in this area should be continued with larger sample sizes and longer follow-up periods
Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies:a case series
Advanced Access publication on May 7, 2014Non-tubal ectopic pregnancies are a rare subgroup of ectopic pregnancies implanted at sites other than the Fallopian tube. Mortality from non-tubal ectopic pregnancies is higher compared with that for tubal ectopic pregnancies, and they are becoming more common, partly due to the rising incidence of Caesarean sections and use of assisted reproductive technologies. Non-tubal ectopic pregnancies can be especially difficult to treat. Surgical treatment is complex, and follow-up after medical treatment is usually protracted. There is therefore a need for more effective medical therapies to resolve non-tubal ectopic pregnancies and reduce operative intervention. We have recently reported successful use of combination gefitinib (an orally available epidermal growth factor receptor inhibitor) and methotrexate for treatment of tubal pregnancies. To our knowledge, this combination has not been used to treat non-tubal pregnancies. Here we report the use of combination gefitinib and methotrexate to treat eight women with stable, non-tubal ectopic pregnancies at two tertiary academic teaching hospitals (Edinburgh, UK and Melbourne, Australia); five interstitial and three Caesarean section scar ectopic pregnancies. Pretreatment serum hCG levels ranged from 2458 to 48 550 IU/l, and six women had pretreatment hCG levels >5000 IU/l. The women were co-administered 1-2 doses of i.m. methotrexate (50 mg/mÂČ on Day 1, ± Day 4 or Day 7) with seven once daily doses of oral gefitinib (250 mg). The women were monitored until complete resolution of the ectopic pregnancy, defined as a serum hCG <15 IU/l. Time to resolution (days from first methotrexate dose until serum hCG <15 IU/l), safety and tolerability, complication rates and subsequent fertility outcomes were also recorded. All eight women were successfully treated with combination gefitinib and methotrexate. The most common side effects were transient acne/rash and diarrhoea, known side effects of gefitinib. All women promptly resumed menstruation and importantly, three women subsequently conceived spontaneously. Two have delivered a healthy infant at term and the third is currently in her second trimester of pregnancy. Hence, our case series supports a future clinical trial to determine the efficacy of combination gefitinib and methotrexate to treat non-tubal ectopic pregnancies.A.W. Horne, M.M. Skubisz, S. Tong, W.C. Duncan, P. Neil, E.M.Wallace, and T.G. John
Model-independent search for CP violation in D0âKâK+ÏâÏ+ and D0âÏâÏ+Ï+Ïâ decays
A search for CP violation in the phase-space structures of D0 and View the MathML source decays to the final states KâK+ÏâÏ+ and ÏâÏ+Ï+Ïâ is presented. The search is carried out with a data set corresponding to an integrated luminosity of 1.0 fbâ1 collected in 2011 by the LHCb experiment in pp collisions at a centre-of-mass energy of 7 TeV. For the KâK+ÏâÏ+ final state, the four-body phase space is divided into 32 bins, each bin with approximately 1800 decays. The p-value under the hypothesis of no CP violation is 9.1%, and in no bin is a CP asymmetry greater than 6.5% observed. The phase space of the ÏâÏ+Ï+Ïâ final state is partitioned into 128 bins, each bin with approximately 2500 decays. The p-value under the hypothesis of no CP violation is 41%, and in no bin is a CP asymmetry greater than 5.5% observed. All results are consistent with the hypothesis of no CP violation at the current sensitivity
Search for the lepton-flavor-violating decays Bs0âe±Όâ and B0âe±Όâ
A search for the lepton-flavor-violating decays Bs0âe±Όâ and B0âe±Όâ is performed with a data sample, corresponding to an integrated luminosity of 1.0ââfb-1 of pp collisions at âs=7ââTeV, collected by the LHCb experiment. The observed number of Bs0âe±Όâ and B0âe±Όâ candidates is consistent with background expectations. Upper limits on the branching fractions of both decays are determined to be B(Bs0âe±Όâ)101ââTeV/c2 and MLQ(B0âe±Όâ)>126ââTeV/c2 at 95% C.L., and are a factor of 2 higher than the previous bounds
Branching fraction and CP asymmetry of the decays B+âK0SÏ+ and B+âK0SK+
An analysis of B+ â K0
SÏ+ and B+ â K0
S K+ decays is performed with the LHCb experiment. The pp
collision data used correspond to integrated luminosities of 1 fbâ1 and 2 fbâ1 collected at centre-ofmass
energies of
â
s = 7 TeV and
â
s = 8 TeV, respectively. The ratio of branching fractions and the
direct CP asymmetries are measured to be B(B+ â K0
S K+
)/B(B+ â K0
SÏ+
) = 0.064 ± 0.009 (stat.) ±
0.004 (syst.), ACP(B+ â K0
SÏ+
) = â0.022 ± 0.025 (stat.) ± 0.010 (syst.) and ACP(B+ â K0
S K+
) =
â0.21 ± 0.14 (stat.) ± 0.01 (syst.). The data sample taken at
â
s = 7 TeV is used to search for
B+
c
â K0
S K+ decays and results in the upper limit ( fc · B(B+
c
â K0
S K+
))/( fu · B(B+ â K0
SÏ+
)) <
5.8 Ă 10â2 at 90% confidence level, where fc and fu denote the hadronisation fractions of a ÂŻb
quark
into a B+
c or a B+ meson, respectively
- âŠ